第8回厚生科学審議会予防接種・ワクチン分科会 研究開発及び生産・流通部会 季節性インフルエンザワクチンの製造株について検討する小委員会	資料 2－2
2023（令和５）年４月24日	

Overview

The WHO recommends that trivalent vaccines for use in the 2023-2024 northern hemisphere influenza season contain the following:

Egg-based vaccines

- **an A/Victoria/4897/2022 (H1N1)pdm09-like virus;**
- **an A/Darwin/9/2021 (H3N2)-like virus; and**
- **a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.**

Cell culture- or recombinant-based vaccines

- **an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;**
- **an A/Darwin/6/2021 (H3N2)-like virus; and**
- **a B/Austria/1359417/2021 (B/Victoria lineage)-like virus**

For quadrivalent egg- or cell culture-based or recombinant vaccines for use in the 2023-2024 northern hemisphere influenza season, the WHO recommends inclusion of the following as the B/Yamagata lineage component:

- **a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.**

引用元：WHOウェブサイト

https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season

World Health Organization

Influenza A(H1N1)pdm09 egg-derived[1] candidate vaccine viruses for development and production of vaccines for use in the 2023-2024 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

25 February 2023 (*last updated 7 March 2023*)

Candidate vaccine viruses (CVVs) antigenically like A/Victoria/4897/2022 (egg-derived) - Accession number (GISAID): EPI_ISL_16714268

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Victoria/4897/2022	Wild type virus			WHO CCs MHRA, UK
	IVR-238	Classical	Seqirus	CCDC, China MHRA, UK VIDRL, Australia

引用元：WHOウェブサイト

https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses

World Health Organization

Influenza A(H3N2) egg-derived [1] candidate vaccine viruses for development and production of vaccines for use in the 2023-2024 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

25 February 2023

Candidate vaccine viruses (antigenically like A/Darwin/9/2021 (egg derived) – Accession number (GISAID): EPI_ISL_2233240

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Darwin/9/2021	Wild type virus			WHO CCs MHRA, UK
	NYMC X-369A	Classical	NYMC	WHO CCs MHRA, UK NYMC, USA
	CBER-47A	Classical	CBER/FDA	CBER/FDA, USA
	CBER-47B			
	SAN-010	Classical	Sanofi	Sanofi, USA MHRA, UK NIID, Japan
	NIB-126	Classical	NIBSC	MHRA, UK NIID, Japan
	IVR-228	Classical	Seqirus	WHO CCs MHRA, UK
A/Darwin/6/2021	Wild type virus			WHO CCs MHRA, UK
	NYMC X-367A	Classical	NYMC	WHO CCs MHRA, UK NYMC, USA
	NIB-127	Classical	NIBSC	MHRA, UK NIID, Japan
	IVR-227	Classical	Seqirus	WHO CCs MHRA, UK
A/Michigan/173/2020	Wild type virus			WHO CCs MHRA, UK

引用元：WHOウェブサイト

https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses

World Health Organization

Influenza B Victoria lineage egg-derived[1] candidate vaccine viruses for development and production of vaccines for use in the 2023-2024 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

25 February 2023

Candidate vaccine viruses (antigenically like B/Austria/1359417/2021 (egg derived) - Accession number (GISAID): EPI_ISL_1519459

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Austria/1359417/2021	Wild type virus			WHO CCs MHRA, UK
	BVR-26	Classical	Seqirus	VIDRL, Australia MHRA, UK NIID, Japan
	BX-107A	Classical	NYMC	CDC, USA MHRA, UK NYMC, USA
B/Michigan/01/2021	Wild type virus			CDC, USA MHRA, UK NIID, Japan
B/Singapore/WUH4618/2021	Wild type virus			WHO CCs MHRA, UK
B/Guangdong-Zhenjiang/1516/2021	Wild type virus			WHO CCs MHRA, UK
	CNIC-2107A	Classical	CCDC, China	WHO CCs

引用元：WHOウェブサイト

https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses

World Health Organization

Influenza B Yamagata lineage egg-derived[1] candidate vaccine viruses for development and production of vaccines for use in the 2023-2024 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

25 February 2023

Candidate vaccine viruses (antigenically like B/Phuket/3073/2013 (egg derived) - Accession number (GISAID): EPI_ISL_168822

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Phuket/3073/2013	Wild type virus			WHO CCs MHRA, UK
	BVR-1B	Classical	Seqirus	VIDRL, Australia
B/California/12/2015		Wild type virus		CDC, USA
	BX-59A	Classical	NYMC	MHRA, UK NYMC, USA
	BX-59B	Classical	NYMC	MHRA,UK NYMC, USA
B/Brisbane/9/2014	Wild type virus			WHO CCs MHRA, UK
B/Utah/09/2014	Wild type virus			CDC, USA MHRA, UK
B/Arizona/10/2015	BX-63	Classical	NYMC	MHRA, UK NYMC, USA
	BX-63A	Classical	NYMC	MHRA, UK NYMC, USA
B/Hong Kong/3417/2014	Wild type virus			NYMC, USA
	BX-57	Classical	NYMC	MHRA, UK NYMC, USA

引用元：WHOウェブサイト

https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses